QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT04898543)
Phase 1 Open-Label Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a two-part, open-label phase 1 study to evaluate safety and preliminary efficacy of M-CENK Suspension for Infusion, Cryopreserved, and N-803 for subcutaneous administration in subjects with locally advanced or metastatic solid tumors. The study consists of two cohorts: cohort 1 includes subjects with either newly diagnosed solid tumors who have not received prior therapy or subjects who have received prior first line treatment; and cohort 2 that includes subjects with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies. The two cohorts will be conducted simultaneously.
Who can join: Review the eligibility criteria below.
Location: Chan Soon-Shiong Institute for Medicine — El Segundo, California
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Chan Soon-Shiong Institute for Medicine — El Segundo, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Solid Tumor
- A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors — Orlando, Florida
- Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS — Coral Gables, Florida
- Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) — Baltimore, Maryland
- TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) — Los Angeles, California
- Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors — Anchorage, Alaska
Explore by condition: All Metastatic Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.